

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/P407FEA1225EN.html>

Date: September 2018

Pages: 73

Price: US\$ 3,500.00 (Single User License)

ID: P407FEA1225EN

Abstracts

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2018

SUMMARY

According to the recently published report 'Placenta Growth Factor - Pipeline Review, H2 2018'; Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 13 molecules.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.

The report 'Placenta Growth Factor - Pipeline Review, H2 2018' outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules

developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 1, 5 and 3 respectively. Report covers products from therapy areas Metabolic Disorders, Ophthalmology and Oncology which include indications Diabetic Macular Edema, Wet (Neovascular/Exudative) Macular Degeneration, Diabetic Retinopathy, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Macular Edema, Retinal Vein Occlusion, Medulloblastoma, Metastatic Colorectal Cancer, Myopia, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy and Retinopathy.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects

The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -
Overview

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -
Companies Involved in Therapeutics Development

Alteogen Inc

Benitec Biopharma Ltd

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Coherus BioSciences Inc

Formycon AG

Lupin Ltd

Momenta Pharmaceuticals Inc

Oxurion NV

Regeneron Pharmaceuticals Inc

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -
Drug Profiles

(aflibercept + nesvacumab) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
afibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
afibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
afibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
afibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
afibercept SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
conbercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

THR-317 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ziv-aflibercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -

Dormant Products

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -

Discontinued Products

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -

Product Development Milestones

Featured News & Press Releases

Aug 17, 2018: FDA approves EYLEA (aflibercept) injection sBLA in wet age-related macular degeneration

Aug 13, 2018: Regeneron Provides Regulatory Update on EYLEA (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration

Aug 01, 2018: Bayer receives approval of new treatment regimen for Eylea in the EU

Jul 19, 2018: ThromboGenics Reports Day 150 Top line Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PIGF) for the Treatment of Diabetic Macular Edema

Jun 13, 2018: FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy

May 23, 2018: ThromboGenics to present a preclinical overview of its most advanced diabetic eye disease clinical candidate, THR-317, at EASDec 2018

May 11, 2018: Bayer receives approval for Eylea in China

Apr 27, 2018: ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PIGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME

Apr 04, 2018: ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317

Mar 20, 2018: Aflibercept shows promising data for non proliferative DR

Mar 19, 2018: EYLEA (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial

Feb 28, 2018: Regeneron Letter to Healthcare Professionals Re: EYLEA (aflibercept) Injection

Feb 13, 2018: Bayer Receives First Approval for Eylea in China

Feb 12, 2018: New data for aflibercept show prolonged injection intervals

Jan 03, 2018: Momenta and Mylan Announce Development Strategy for M710, a

Proposed Biosimilar to EYLEA (aflibercept)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Alteogen Inc, H2 2018
Pipeline by Benitec Biopharma Ltd, H2 2018
Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2018
Pipeline by Coherus BioSciences Inc, H2 2018
Pipeline by Formycon AG, H2 2018
Pipeline by Lupin Ltd, H2 2018
Pipeline by Momenta Pharmaceuticals Inc, H2 2018
Pipeline by Oxurion NV, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Alteogen Inc

Benitec Biopharma Ltd

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Coherus BioSciences Inc

Formycon AG

Lupin Ltd

Momenta Pharmaceuticals Inc

Oxurion NV

Regeneron Pharmaceuticals Inc

I would like to order

Product name: Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/P407FEA1225EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P407FEA1225EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

